MURALI CHINTAGUMPALA to Risk Assessment
This is a "connection" page, showing publications MURALI CHINTAGUMPALA has written about Risk Assessment.
Connection Strength
0.099
-
Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). J Clin Oncol. 2021 03 01; 39(7):822-835.
Score: 0.024
-
Study of Unilateral Retinoblastoma With and Without Histopathologic High-Risk Features and the Role of Adjuvant Chemotherapy: A Children's Oncology Group Study. J Clin Oncol. 2019 11 01; 37(31):2883-2891.
Score: 0.022
-
Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer. J Neurosurg Pediatr. 2015 Jul; 16(1):4-13.
Score: 0.016
-
Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009 Aug; 133(8):1199-202.
Score: 0.011
-
Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008 Aug 01; 26(22):3749-55.
Score: 0.010
-
Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study. J Clin Oncol. 2007 Jul 20; 25(21):3130-6.
Score: 0.009
-
Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004 Mar 15; 22(6):984-93.
Score: 0.007